Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

wakamoto pharmaceutical co., ltd - fluorometholone - white or milky white ophthalmic suspension, (cap) deep pink

Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

rohto nitten co., ltd. - fluorometholone - white ophthalmic suspension when shaken, (cap) light gray, (bottle) white translucent, (accompanying bag) clear

Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

nitto medic co., ltd. - fluorometholone - slightly viscous and white sterile ophthalmic suspention, 5ml, (cap) baby pink, (label) clear label with baby pink band, (bottle) clear

Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

nitto medic co., ltd. - fluorometholone - slightly viscous and white sterile ophthalmic suspention, 5ml, (cap) pink, (label) clear label with pink band, (bottle) clear

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - fluorometholone 0.1%{relative} (+5% overage) - eye drops, suspension - 0.1% w/v - active: fluorometholone 0.1%{relative} (+5% overage) excipient: benzalkonium chloride dibasic sodium phosphate disodium edetate dihydrate hydrochloric acid hypromellose monobasic sodium phosphate monohydrate polysorbate 80 polyvinyl alcohol purified water sodium chloride sodium hydroxide

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - fluorometholone 1 mg/ml - eye drops, solution - 0.1% w/v - active: fluorometholone 1 mg/ml excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 polyvinyl alcohol purified water sodium chloride sodium edetate sodium hydroxide

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

novartis ophthalmics - fluorometholone (unii: sv0csg527l) (fluorometholone - unii:sv0csg527l) - suspension - 0.1 ml in 100 ml - fluor-op is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. fluor-op suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. fluor-op suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

allergan, inc. - fluorometholone (unii: sv0csg527l) (fluorometholone - unii:sv0csg527l), sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - suspension - 1.0 mg in 1 ml - fml-s® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: esche

Kanāda - angļu - Health Canada

abbvie corporation - fluorometholone - suspension - 0.1% - fluorometholone 0.1% - corticosteroids

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluorometholone -